Spherix Global Insights Announces Upcoming New Special TopixTM Unpacking Payer Management Strategies Across Over 25 Therapeutic Areas

Key Takeaways:

• Spherix Global Insights will release a Special Topix™ service titled “Payer Management Strategies.”
• The study spans more than 25 therapeutic areas, from lupus to oncology.
• Findings draw on qualitative and quantitative research with executives at national, Blues and regional health plans and PBMs.
• Topics include formulary design, contracting pressures, biosimilar strategies and the Inflation Reduction Act.
• Subscribed clients will receive the report at the end of August 2025.

Introduction
EXTON, Pa.—Spherix Global Insights is betting that better intel on insurers will translate into better drug-launch decisions. The market-research firm announced the forthcoming release of its Special Topix™ report, “Payer Management Strategies,” a guide to how U.S. payers intend to handle access and reimbursement in the coming year.

What the Report Promises
According to Spherix, the service delivers “critical, forward-looking intelligence into payer priorities, strategies, and evolving access dynamics.” At its core, the study aims to help pharmaceutical stakeholders anticipate shifts that could open—or slam—doors to key medications.

Who Was Asked
The intelligence is drawn from a blended qualitative and quantitative survey of pharmacy and medical executives “representing the leading national, Blues plans, and regional health plans and PBMs.” By tapping the decision makers who design formularies and negotiate contracts, Spherix says it can map the forces that ultimately shape patient access.

Why Timing Matters
Rising pressure to contain drug costs, coupled with sweeping policy changes like the Inflation Reduction Act, has placed market-access strategy under a microscope. Spherix positions its report as a compass for navigating those disruptions, with sections devoted to how payers expect to apply the IRA’s provisions.

Breadth of Therapeutic Coverage
The analysis stretches across “a broad range of therapeutic categories”—more than 25 in all—covering conditions flagged by Spherix’s keyword set, including lupus, atopic dermatitis, oncology and multiple sclerosis. For each area, the report explores formulary tiers, step-therapy requirements, and potential biosimilar shake-ups.

Delivery and Next Steps
Subscribers can expect the report “at the end of the month.” With that deadline approaching, pharmaceutical teams are lining up to digest the findings—and adjust their launch, pricing and contracting tactics before payers make their next move.